Black Diamond Therapeutics, Inc. BDTX
1.88
(0.02)
(1.05%)
as of 25 Sep
- Market cap
- $108.6M
- P/E
- 0.0×
Follow BDTX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (37.21%) | (35.16%) | 22.88% | 19.23% |
+8 more TTM periods Free account |
|
| (29.21%) | (27.95%) | 16.84% | 14.54% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(42.61%) | (39.73%) | 19.11% | 17.26% | |
Free Cash Flow per Share |
(0.57) | (0.59) | 0.52 | 0.38 | |
Free Cash Flow |
(32.84) | (34.03) | 29.64 | 21.38 | |
Capital Expenditures |
— | — | 0.03 | 0.03 | |
| Other line items | |||||
Cash ROIC |
(15.89%) | (15.29%) | 12.29% | 8.16% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.79 | 1.32 | 0.99 | |
Depreciation/Fixed assets |
0.67 | 0.78 | 0.89 | 0.31 | |
Capex/Depreciation |
0.00 | 0.00 | 0.08 | 0.09 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.57) | (0.59) | 0.52 | 0.38 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates